JPMorgan Chase & Co. Reiterates “Neutral” Rating for Amgen (AMGN)

JPMorgan Chase & Co. restated their neutral rating on shares of Amgen (NASDAQ:AMGN) in a research report sent to investors on Thursday morning.

A number of other equities research analysts have also issued reports on the stock. Cann reaffirmed a buy rating and set a $224.00 target price on shares of Amgen in a report on Monday, October 1st. Royal Bank of Canada reaffirmed a neutral rating and set a $193.00 target price on shares of Amgen in a report on Monday, September 10th. Oppenheimer reaffirmed a buy rating and set a $224.00 target price on shares of Amgen in a report on Tuesday, August 28th. Jefferies Financial Group set a $220.00 target price on shares of Amgen and gave the stock a buy rating in a report on Wednesday, September 12th. Finally, Mizuho reissued a buy rating and issued a $200.00 price objective on shares of Amgen in a report on Friday, July 27th. One analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and eleven have issued a buy rating to the company’s stock. Amgen currently has an average rating of Hold and an average target price of $205.16.

Amgen stock opened at $185.98 on Thursday. Amgen has a 52-week low of $163.31 and a 52-week high of $210.19. The firm has a market cap of $120.38 billion, a PE ratio of 14.78, a price-to-earnings-growth ratio of 1.80 and a beta of 1.40. The company has a quick ratio of 3.12, a current ratio of 3.39 and a debt-to-equity ratio of 2.03.



The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 7th. Investors of record on Friday, November 16th will be issued a $1.32 dividend. This represents a $5.28 dividend on an annualized basis and a dividend yield of 2.84%. The ex-dividend date is Thursday, November 15th. Amgen’s dividend payout ratio is currently 41.97%.

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Kwmg LLC purchased a new position in Amgen during the second quarter worth about $108,000. Mainstay Capital Management LLC ADV purchased a new position in Amgen during the second quarter worth about $111,000. Polaris Greystone Financial Group LLC purchased a new position in Amgen during the third quarter worth about $166,000. Mount Yale Investment Advisors LLC purchased a new position in Amgen during the first quarter worth about $181,000. Finally, Dixon Hubard Feinour & Brown Inc. VA purchased a new position in Amgen during the second quarter worth about $200,000. 82.37% of the stock is owned by hedge funds and other institutional investors.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.

Recommended Story: Stop Order Uses For Individual Investors

Analyst Recommendations for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply